Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland
Higher PD-L1 levels don't meaningfully predict immunotherapy response in triple-negative breast cancer, simplifying treatment decisions.
In 72 real-world PD-L1-positive mTNBC patients from 13 Polish centers, CPS as a continuous variable had no clinically meaningful association with treatment response or survival on pembrolizumab-based first-line therapy. These findings challenge the utility of higher CPS values as a predictive biomarker beyond the eligibility threshold, informing shared decision-making in mTNBC.
What the study was
- Study design
- Multicenter retrospective real-world study
- Population
- PD-L1-positive (CPS≥10) mTNBC, first-line pembrolizumab+chemotherapy, 13 Polish oncology centers 2022–2025; n=72
- Sample size
- 72
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Clinical and Translational Oncology
Why it surfaced
Real-world multicenter data on CPS predictive value; directly relevant to clinical practice; small n=72 limits statistical power; retroactive; supports threshold-only use of CPS.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.